SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC
Launched by THE UNIVERSITY OF HONG KONG · Jul 4, 2018
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • HCC confined to single lobe of non-cirrhotic liver (locally advanced) and not suitable for surgery or loco-regional therapies at the time of study entry, but can become resectable after treatment
- • Diagnosis of HCC confirmed by histology
- • Child-Pugh class A cirrhosis with adequate remnant liver parenchyma
- • Measurable disease
- • Fit enough to undergo surgery to resect the primary liver tumour
- Exclusion Criteria:
- • Prior systemic therapy for HCC
- • Presence of extrahepatic metastasis
- • History of liver transplantation
- • Peripheral sensory neuropathy with functional impairment
- • Uncontrolled hypertension/ cardiac disease
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials